EUVIMEDEUVIMED entdecken
Crossref

Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity

Yingqi Liu iD, Fan Meng, Wanting Feng, Zehong Chen, Haonan Xing iD, Aiping Zheng

Molecular Pharmaceutics · 03.03.2025 · 22 (3) · 1241-1252

DOI: 10.1021/acs.molpharmaceut.4c00943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 17.02.2025. Verfasst von Yingqi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China. Hauptthemen laut MEDLINE: Lectins, C-Type, Cell Wall, Immunity, Mucosal, Vaccines, DNA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucosal vaccines can generate localized mucosal immunity, effectively preventing initial pathogen infection and providing more effective protection. Oral vaccines are an attractive option for inducing mucosal immunity. The yeast cell wall, primarily composed of natural β-1,3-d glucan, can be recognized by the apical membrane receptor, dectin-1, which has a high expression on macrophages and intestinal M cells. In this study, by using vortexing methods to break yeast cell walls into nanometer-sized fragments, which retain the negatively charged β-glucan components on their surface and employing electrostatic adsorption/coextrusion techniques, these fragments were attached onto the surface of PS-DNA NPs, as verified by a scanning electron microscope (SEM), a transmission electron microscope (TEM), and dynamic light scattering (DLS) data. YCW-coated NPs (YNPs) showed greater drug stability compared to NPs in a simulated gastrointestinal environment. In vitro cell evaluation further demonstrated that YNPs were rapidly and efficiently taken up by antigen-presenting cells via receptor dectin-1-mediated endocytosis. In vivo experiments revealed that the oral vaccine elicited high levels of RBD-specific antibodies and triggered extensive cellular immunity in the intestinal mucosa. This study provides new insights into mucosal vaccine research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lectins, C-TypeCell WallImmunity, MucosalVaccines, DNASaccharomyces cerevisiaeAnimalsMiceAdministration, OralMice, Inbred BALB CFemaleNanoparticlesbeta-GlucansHumansDectin-1

Stichwörter der Autor:innen

dectin-1mucosal immunityoral vaccinesprotamineyeast cell wall

Substanzen

Lectins, C-TypeVaccines, DNAbeta-GlucansDectin-1

Autor:innen und Institutionen

  • Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.

ORCID-Profile: Yingqi Liu, Haonan Xing

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., Meng, F., Feng, W., Chen, Z., Xing, H., & Zheng, A. (2025). Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity. Molecular Pharmaceutics, 22(3), 1241-1252. https://doi.org/10.1021/acs.molpharmaceut.4c00943

Vancouver

Liu Y, Meng F, Feng W, Chen Z, Xing H, Zheng A. Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity. Molecular Pharmaceutics. 2025;22(3):1241-1252. doi:10.1021/acs.molpharmaceut.4c00943

BibTeX
@article{Liu2025,
  author = {Liu, Yingqi and Meng, Fan and Feng, Wanting and Chen, Zehong and Xing, Haonan and Zheng, Aiping},
  title = {Oral DNA Vaccine Utilizing the Yeast Cell Wall for Dectin-1 Receptor-Mediated Enhancement of Mucosal Immunity},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {3},
  pages = {1241--1252},
  doi = {10.1021/acs.molpharmaceut.4c00943}
}
Kostenlos starten →